| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/07/2002 | WO2001060414A3 Genetic modification of the lung as a portal for gene delivery |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001056983A3 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055219A3 scsCNTFR/NNT-1 FUSION PROTEIN |
| 03/07/2002 | WO2001053468A3 Lipid metabolism enzymes and polynucleotides encoding them |
| 03/07/2002 | WO2001051636A3 Secreted proteins |
| 03/07/2002 | WO2001046231A3 Polynucleotides and polypeptides encoded thereby |
| 03/07/2002 | WO2001046166A3 Partially saturated calcium channel blockers |
| 03/07/2002 | WO2001043692A3 SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001031008A3 Human and rat fgf-20 genes and gene expression products |
| 03/07/2002 | WO2001028591A3 Injection vehicle for polymer-based formulations |
| 03/07/2002 | WO2001024831A3 Polymer stabilized neuropeptides |
| 03/07/2002 | WO2001023377A3 Polymorphic salt |
| 03/07/2002 | WO2001019870A3 Secreted soluble alpha2delta-2, alpha2delta-3, alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 03/07/2002 | WO2001001974A3 Naaladase inhibitors in anxiety and memory disorders |
| 03/07/2002 | WO2000073344A9 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 03/07/2002 | US20020028942 Freeze-dried form of paroxetine hydrochloride suitable for parenteral administration; treatment and prophylaxis of depression, obsessive compulsive disorder and panic disorders |
| 03/07/2002 | US20020028925 Hsv viral vector |
| 03/07/2002 | US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides |
| 03/07/2002 | US20020028841 Thienopyrrolidinones |
| 03/07/2002 | US20020028836 Potassium channel openers |
| 03/07/2002 | US20020028835 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 03/07/2002 | US20020028826 HMG-CoA reductase inhibitors and method |
| 03/07/2002 | US20020028821 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
| 03/07/2002 | US20020028818 2-nitrostyryl-1-(naphthylmethyl)sulfone for example |
| 03/07/2002 | US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents |
| 03/07/2002 | US20020028815 Novel multicyclic compounds and the use thereof |
| 03/07/2002 | US20020028814 Aza compounds, pharmaceutical compositions and methods of use |
| 03/07/2002 | US20020028812 Phenylalanine derivatives |
| 03/07/2002 | US20020028809 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors |
| 03/07/2002 | US20020028803 Controlling cell apoptosis |
| 03/07/2002 | US20020028802 Solvent extraction; plant extracts |
| 03/07/2002 | US20020028790 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity |
| 03/07/2002 | US20020028787 Nervous system disorders; administering exogenous uridine compound |
| 03/07/2002 | US20020028782 Cardiovascular disorders; nervous system disorders |
| 03/07/2002 | US20020028775 Using mixture of flavonoids, cytochrome inhibitor, sugar, phosphate in carrier |
| 03/07/2002 | US20020028774 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/07/2002 | US20020028772 Modulation of metabolism |
| 03/07/2002 | US20020028514 Recombinant AAV vector-based transduction system and use of same |
| 03/07/2002 | US20020028510 Cells for use in the treatment of nervous system disorders |
| 03/07/2002 | US20020028246 Neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose; immediate-release |
| 03/07/2002 | US20020028244 Biodegradable neurotoxin implant |
| 03/07/2002 | US20020028238 Orally administration to provide a blood plasma concentration profile of celecoxib of at least about 250 mg/ml in not more than about 30 minutes |
| 03/07/2002 | US20020028216 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | US20020028199 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC) |
| 03/07/2002 | DE10042093A1 Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung Anticonvulsant acting 6,7-dihydro-pyrrolo [3,4-d] pyridin-5-one and processes for their representation |
| 03/07/2002 | DE10042092A1 Antikonvulsiv wirkende 2,5-Dihydro-pyrazolo(3,4-d)pyrimidin-4-one und Verfahren zu deren Darstellung Anticonvulsant acting 2,5-dihydro-pyrazolo (3,4-d) pyrimidin-4-one and processes for their representation |
| 03/07/2002 | DE10041574A1 Chromenonderivate Chromenonderivate |
| 03/07/2002 | DE10041238A1 Verfahren zur Identifizierung spezifisch spaltbarer peptide und Verwendung solcher Peptidsequenzen A method for identifying specific cleavable peptide and use of such peptide sequences |
| 03/07/2002 | DE10040933A1 Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen Use of beta-mannosylglycerate (firoin) and / or derivatives, in particular the beta-mannosylglyceramide (firoin-A), in cosmetic and dermatological formulations |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2424146A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | CA2424052A1 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | CA2424026A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | CA2424011A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2421055A1 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | CA2420987A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
| 03/07/2002 | CA2420969A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors |
| 03/07/2002 | CA2420935A1 N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide |
| 03/07/2002 | CA2420906A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | CA2420900A1 Thrombomodulin analogs for use in recovery of signal cord injury |
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | CA2420696A1 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof |
| 03/07/2002 | CA2420667A1 Quinoline-(c=o)-(di-,tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420569A1 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420288A1 2,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonvulsive action and methods for producing the same |
| 03/07/2002 | CA2420286A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2419841A1 Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | CA2419623A1 Method for treatment of migraine using pde5 inhibitors |
| 03/07/2002 | CA2419561A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419342A1 G-protein coupled receptors |
| 03/07/2002 | CA2419256A1 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | CA2418038A1 Paroxetine compositions and processes for making the same |
| 03/07/2002 | CA2417136A1 Proteins related to schizophrenia and uses thereof |
| 03/06/2002 | EP1184454A2 Nav2 channel gene-deficient non-human animals |
| 03/06/2002 | EP1184385A1 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| 03/06/2002 | EP1184384A1 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives |
| 03/06/2002 | EP1184383A1 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
| 03/06/2002 | EP1184372A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) |
| 03/06/2002 | EP1184367A1 Amide derivatives |
| 03/06/2002 | EP1184036A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 03/06/2002 | EP1183386A1 Tm4sf receptors |
| 03/06/2002 | EP1183384A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 03/06/2002 | EP1183370A2 Human oxidoreductase proteins |
| 03/06/2002 | EP1183364A1 Groel muteins with improved stability |
| 03/06/2002 | EP1183359A2 Nucleic acids and proteins with interferon-beta activity |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |